ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

TENX Tenax Therapeutics Inc

3,14
-0,06 (-1,88%)
15 Jun 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Tenax Therapeutics Inc TENX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,06 -1,88% 3,14 06:00:02
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,23 3,08 3,32 3,14 3,20
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
13.6.202422:32EDGAR2Form 8-K - Current report
24.5.202422:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
21.5.202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.5.202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.5.202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14.5.202415:01EDGAR2Form 8-K - Current report
14.5.202414:00GLOBETenax Therapeutics Reports First Quarter 2024 Financial..
30.4.202413:30GLOBETenax Therapeutics Announces New U.S. Patent Covering the..
09.4.202414:30GLOBETenax Therapeutics to Host KOL Event: “LEVEL Setting: the..
28.3.202413:30GLOBETenax Therapeutics Provides Business and Clinical..
12.3.202413:30GLOBETenax Therapeutics to Present at the 36th Annual Roth..
29.2.202415:00GLOBETenax Therapeutics Announces Oral Presentation of..
23.2.202422:30EDGAR2Form 8-K - Current report
20.2.202422:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
20.2.202414:33EDGAR2Form 8-K - Current report
20.2.202414:30GLOBETenax Therapeutics Announces Global License Amendment that..
16.2.202417:28EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16.2.202401:36EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12.2.202422:46EDGAR2Form 8-K - Current report
08.2.202414:16GLOBETenax Therapeutics Announces Pricing of Approximately $9..
08.2.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
08.2.202402:01GLOBETenax Therapeutics Enrolls First Patient in Phase 3 LEVEL..
06.2.202414:56EDGAR2Form 8-K - Current report
06.2.202414:30GLOBETenax Therapeutics Announces USPTO Grants Notice of..
02.2.202423:24EDGAR2Form S-1/A - General form for registration of securities..
01.2.202422:20EDGAR2Form S-1/A - General form for registration of securities..
19.1.202422:30EDGAR2Form 8-K - Current report
12.1.202423:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
12.1.202422:30EDGAR2Form 8-K - Current report
05.1.202422:46EDGAR2Form 8-K - Current report
01.12.202322:47EDGAR2Form S-1 - General form for registration of securities under..
01.12.202322:01EDGAR2Form 8-K - Current report
17.11.202314:30GLOBETenax Therapeutics Announces Professor Javed Butler, M.D.,..
14.11.202322:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
13.11.202322:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.11.202315:10EDGAR2Form 8-K - Current report
13.11.202314:30GLOBETenax Therapeutics Announces FDA Clearance of IND for..
29.9.202322:11EDGAR2Form 8-K - Current report
15.8.202322:05EDGAR2Form 8-K - Current report
14.8.202322:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
19.7.202322:30EDGAR2Form 8-K - Current report
19.7.202314:30GLOBETenax Therapeutics Issued U.S. Patent for Oral Levosimendan..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock